Atherectomy for peripheral artery disease

Series
Peripheral vascular interventions
Status
Published
Date
Number of report
011

Ask the expert

(we accept only company emails)

Report presents summary of the reimbursement situation in Europe for atherectomy.

Analysis covers iliac, femoral and popliteal arteries.

Analysis is provided for admitted and day case hospital care.

The following clinical scenarios are considered:

  • Percutaneous transluminal atherectomy as stand-alone procedure
  • Percutaneous transluminal atherectomy in combination with plain balloon angioplasty
  • Percutaneous transluminal atherectomy in combination with insertion of bare metal stent
  • Percutaneous transluminal atherectomy in combination with plain balloon angioplasty and insertion of bare metal stent

Report includes essential information about reimbursement and national funding for atherectomy, including:

  • Brief overview of reimbursement system for medical devices
  • Procedure coding for technology
  • Diagnosis coding
  • Payment mechanism for technology
  • Reimbursement tariffs for technology
  • Restrictions in indications or scenarios for use of technology
  • Policy considerations by payers and policy-makers about technology

Reimbursement information is provided for the following geographies:

  • Austria
  • Belgium
  • Denmark
  • England (UK)
  • France
  • Germany
  • Italy
  • Netherlands
  • Norway
  • Sweden
  • Switzerland

It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.

Manufacturers of the atherectomy systems include:

  • Boston Scientific (Jetstream, Rotablator System)
  • Cardiovascular Systems (Diamondback Orbital Atherectomy System)
  • Medtronic (HawkOne directional atherectomy system, TurboHawk plaque excision system, SilverHawk plaque excision system)
  • Philips Volcano (Phoenix atherectomy system)
  • Spectranetics (Turbo-Power Laser Atherectomy Catheter, Turbo-Elite laser atherectomy catheter, Turbo-Tandem Laser Guide Catheter with Laser Atherectomy Catheter)

If you are interested in other reimbursement reports in the peripheral artery field, please, visit report-specific pages for:

Table of content

1.    Introduction and summary
2.
    Executive summary table
3.    Contents
4.    Methodology
5.    Reimbursement analysis in Austria

5.1.    Overview of the reimbursement system
5.2.    Reimbursement for percutaneous atherectomy
5.2.1.    Procedure coding
5.2.1.1.    Coding of atherectomy
5.2.1.2.    Coding of atherectomy in combination with angioplasty and insertion of stent
5.2.2.    Diagnosis coding
5.2.3.    Payment mechanism and reimbursement tariffs
5.2.3.1.    Reimbursement of atherectomy
5.2.3.2.    Reimbursement of atherectomy in combination with angioplasty and insertion of stent
6.    Reimbursement analysis in Belgium
6.1.    Overview of the reimbursement system
6.2.    Reimbursement for percutaneous atherectomy
6.2.1.    Procedure and material coding 
6.2.1.1.    Procedure and material coding of percutaneous transluminal atherectomy
6.2.1.2.    Procedure and material coding for surgical endarterectomy
6.2.2.    Payment mechanism and reimbursement tariffs
7.    Reimbursement analysis in Denmark
7.1.    Overview of the reimbursement system
7.2.    Reimbursement for percutaneous atherectomy
7.2.1.    Procedure coding 
7.2.2.    Diagnosis coding
7.2.3.    Payment mechanism and reimbursement tariffs
8.    Reimbursement analysis in England
8.1.    Overview of the reimbursement system
8.2.    Reimbursement for percutaneous atherectomy
8.2.1.    Procedure coding 
8.2.1.1.    Coding of atherectomy
8.2.1.2.    Coding of angioplasty and insertion of stent
8.2.2.    Diagnosis coding
8.2.3.    Payment mechanism and reimbursement tariffs
8.2.3.1.    Reimbursement for atherectomy
8.2.3.2.    Reimbursement for atherectomy in combination with angioplasty
8.2.3.3.    Reimbursement for atherectomy in combination with angioplasty with insertion of stent
8.2.4.    Policy considerations 
8.2.4.1.    Health technology assessment of percutaneous atherectomy by the National Institute for Health and Care Excellence 
8.2.4.2.    Commissioning of percutaneous atherectomy
9.    Reimbursement analysis in France
9.1.    Overview of the reimbursement system
9.2.    Reimbursement for percutaneous atherectomy
10.    Reimbursement analysis in Germany
10.1.    Overview of the reimbursement system
10.2.    Reimbursement for percutaneous atherectomy
10.2.1.    Procedure coding 
10.2.1.1.    Coding of atherectomy
10.2.1.2.    Coding of atherectomy in combination with angioplasty and insertion of stent
10.2.2.    Diagnosis coding
10.2.3.    Payment mechanism and reimbursement tariffs in hospital setting
10.2.3.1.    Reimbursement for atherectomy
10.2.3.2.    Reimbursement for atherectomy in combination with angioplasty and insertion of stent 
10.2.4.    Payment mechanism and reimbursement tariffs in day case setting
10.2.5.    Policy considerations
11.    Reimbursement analysis in Italy
11.1.    Overview of the reimbursement system
11.2.    Reimbursement for percutaneous atherectomy
11.2.1.    Procedure coding 
11.2.1.1.    Coding of atherectomy
11.2.1.2.    Coding of atherectomy in combination with angioplasty and insertion of stent
11.2.2.    Diagnosis coding
11.2.3.    Payment mechanism and reimbursement tariffs 
11.2.3.1.    Reimbursement for atherectomy
11.2.3.2.    Reimbursement for atherectomy in combination with angioplasty and insertion of stent 
12.    Reimbursement analysis in the Netherlands
12.1.    Overview of the reimbursement system
12.2.    Reimbursement for percutaneous atherectomy
12.2.1.    Procedure coding
12.2.1.1.    Coding of atherectomy
12.2.1.2.    Coding of atherectomy in combination with angioplasty and insertion of stent
12.2.2.    Material coding
12.2.3.    Diagnosis coding
12.2.4.    Payment mechanism and reimbursement tariffs
12.2.4.1.    Reimbursement for atherectomy
12.2.4.2.    Reimbursement for atherectomy in combination with angioplasty
12.2.4.3.    Reimbursement for atherectomy in combination with angioplasty with insertion of stent
12.2.5.    Policy considerations
12.2.6.    Health technology assessment by National Healthcare Institute
13.    Reimbursement analysis in Norway
13.1.    Overview of the reimbursement system
13.2.    Reimbursement for percutaneous atherectomy
13.2.1.    Procedure coding 
13.2.2.    Diagnosis coding
13.2.3.    Payment mechanism and reimbursement tariffs 
13.2.3.1.    Reimbursement using procedure codes for “other image-guided interventions”
13.2.3.2.    Reimbursement for surgical endarterectomy
14.    Reimbursement analysis in Sweden
14.1.    Overview of the reimbursement system
14.2.    Reimbursement for percutaneous atherectomy
14.2.1.    Procedure coding 
14.2.2.    Diagnosis coding
14.2.3.    Payment mechanism and reimbursement tariffs 
15.    Reimbursement analysis in Switzerland
15.1.    Overview of the reimbursement system
15.2.    Reimbursement for percutaneous atherectomy
15.2.1.    Procedure coding 
15.2.1.1.    Coding of atherectomy
15.2.1.2.    Coding of atherectomy in combination with angioplasty and insertion of stent
15.2.2.    Diagnosis coding
15.2.3.    Payment mechanism and reimbursement tariffs in hospital setting
15.2.3.1.    Reimbursement for atherectomy
15.2.3.2.    Reimbursement for atherectomy in combination with angioplasty with insertion of stent
15.2.4.    Payment mechanism and reimbursement tariffs in day case
15.2.4.1.    Reimbursement for atherectomy
15.2.4.2.    Reimbursement for atherectomy in combination with angioplasty with insertion of stent
15.2.5.    Policy considerations 
16.    Disclaimer
 

13

Oct 2021

The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in September 2021. In total, 58 recommendations for registration, modification of registration conditions, and removal of devices from the List of reimbursable products and services (LPPR) were published. Opinions concern cardiovascular, orthopedic, peripheral vascular, and other groups of devices, as well as medical aids.

Read more

23

Sep 2021

The HTA body of the Tuscany Regional Healthcare issues two types of documents: HTA forms and motivational forms. With a regional decree 14763 of August 25, 2021, Tuscany Regional Healthcare has published assessments of thirteen medical devices of various therapeutic areas, including devices belonging to the obstetrics and gynecology field, as well as gastroenterology, urology, cardiovascular, endoscopy, spine, peripheral vascular, and other fields of care.

Read more

15

Jul 2021

The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in June 2021. Recommendations concern cardiovascular and peripheral vascular devices, orthopedic devices, liquid for embolization, and medical aids.

Read more

14

Jun 2021

The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in May 2021. Recommendations concern orthopedic devices, cardiovascular, peripheral vascular, and neurovascular devices, medical aids, and pulmonary artery pressure sensor.

Read more

28

May 2021

In April 2021, the National Institute for Health and Care Excellence (NICE) published three new Interventional Procedure Guidance (repetitive short-pulse transscleral cyclophotocoagulation for glaucoma, deep brain stimulation for chronic, severe, treatment-resistant obsessive-compulsive disorder in adults, and Melphalan chemosaturation for primary or metastatic cancer in the liver) and two Medtech Innovation Briefings (microINR for anticoagulation therapy and RenalSense Clarity RMS for acute kidney injury), and two clinical guidelines (for atrial fibrillation and chronic pain in over 16s).

Read more
(we accept only company emails)